Bayer defeats competition claims in US trial over flea and tick treatment
By Mike Scarcella
Aug 2 (Reuters) -A former unit of German life-sciences giant Bayer convinced a federal jury in California on Thursday that it did not block a pet care startup from competing in the retail market for a type of topical animal tick and flea treatment.
The jury determined in its second day of deliberations in San Jose that plaintiff Tevra Brands had not shown that there was a “relevant” market for the treatments under U.S. antitrust law. The verdict came after a two-week trial.
Tevra had urged the jury to hold Bayer liable for allegedly blocking generic competition for topical flea and tick treatments containing the insecticide imidacloprid as their active ingredient. Tevra accused Bayer of imposing deals on major pet retailers to only feature some Bayer products, causing Tevra to lose tens of millions of dollars in revenue.
Attorneys for Tevra did not immediately respond to a request for comment. They can appeal the verdict to the San Francisco-based 9th U.S. Circuit Court of Appeals.
Bayer sold Bayer Animal Health, a Bayer Healthcare unit, five years ago to Elanco Animal Health ELAN.N in a $7.6 billion deal.
Elanco in a statement welcomed the jury’s verdict and said retailers in the highly competitive pet health market are able to carry a wide variety of products. Bayer denied any wrongdoing.
Hours after the verdict was announced, Tevra sued Elanco in California federal court in a new lawsuit mirroring the allegations in the Bayer case.
Elanco was separately hit with a consumer lawsuit on Wednesdayaccusing it of suppressing competition for its topical flea and tick treatment. That case in Indiana focused in part on Tevra’s effort to sell some of its products at pet specialty stores.
Tevra filed its lawsuit against Bayer Healthcare in 2019, challenging a discount it said Bayer provided to some pet specialty retailers and distributors to exclusively carry its products.
“Tevra went into the marketplace hoping for nothing more than a fair opportunity to sell their product, and they were denied that opportunity because of Bayer’s actions,” Daniel Owen, a lawyer for Tevra, told the jury. He said Bayer's conduct caused consumers to pay higher prices.
Bayer's lawyer Daniel Asimow countered that Tevra’s market definition was too narrow, and that competition should be considered broader than one product Bayer sells versus a generic from Tevra.
Asimow also said Tevra was slow to get to market and had poor relationships with retailers. Bayer competed “vigorously, but ethically” and its discount program was short-term and voluntary, Asimow told the jury.
The case is Tevra Brands LLC v. Bayer Healthcare LLC, U.S. District Court for the Northern District of California, No. 5:19-cv-04312.
For Tevra: Daniel Owen of Polsinelli
For Bayer: Daniel Asimow and Sonia Pfaffenroth of Arnold & Porter Kaye Scholer
Read more:
Advantix maker Elanco hit with price-fixing lawsuit over flea, tick products
Bayer heads to trial in US antitrust lawsuit over flea, tick medication
Reporting by Mike Scarcella
Mga Kaugnay na Asset
Pinakabagong Balita
Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.
Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.
Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.
